The 5th U-PGx Personalized Medicine Day will be organized in Liverpool, UK. The meeting will be co-organized from the Golden Helix Foundation and the University of TLiverpool, both partners of the Ubiquitous Pharmacogenomics (U-PGx) project, funded by the European Commission (H2020-668353).
The event will be held at the Royal Liverpool Hospital postgraduate Medical Centre lecture theatre.
This international event is open for clinical pharmacologists, hospital pharmacists, general pharmacists, specialists, general practitioners, medical students, laboratory technicians, regulators, healthcare insurers and others interested in pharmacogenomics.
On behalf of the Organizing Committee
Co-organized by:  |
 |
Funded by:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668353. |
IntroductionAbout U-PGXSpeakersScientific ProgramRegistrationGalleryThe 5th U-PGx Personalized Medicine Day will be organized in Liverpool, UK. The meeting will be co-organized from the Golden Helix Foundation and the University of TLiverpool, both partners of the Ubiquitous Pharmacogenomics (U-PGx) project, funded by the European Commission (H2020-668353).
The event will be held at the Royal Liverpool Hospital postgraduate Medical Centre lecture theatre.
This international event is open for clinical pharmacologists, hospital pharmacists, general pharmacists, specialists, general practitioners, medical students, laboratory technicians, regulators, healthcare insurers and others interested in pharmacogenomics.
On behalf of the Organizing Committee
| Co-organized by: | | Funded by: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668353 |
Clinical application of pharmacogenomics knowledge will result in less ‘trial and error’ prescribing and more efficacious, safer and cost-effective drug therapy. However, despite the major advances in pharmacogenomics and several commercially available pharmacogenomics tests, its application in routine patient care remains very limited. The U-PGx consortium will address major challenges and obstacles for implementation of pharmacogenomics testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important pharmacogenomics markers is cost-effective and results in a better outcome for patients. With the pre-emptive pharmacogenomics testing approach data on multiple important pharmacogenes are collected prospectively and embedded into the patients’ electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalised medicine through pre-emptive pharmacogenomics testing will be conducted at a large scale in seven existing European health care environments in the Netherlands, Spain, UK, Italy, Austria, Greece, and Slovenia.
Organising Committee
Sir. Munir Pirmohamed, Professor, University of Liverpool, Wolfson Centre for Personalised Medicine, Liverpool, UK
Richard Turner, Post-doctoral Clinical Research Fellow; University of Liverpool, Wolfson Centre for Personalised Medicine, Liverpool, UK
Christina Mitropoulou, Managing Director, The Golden Helix Foundation, London, UK
Keynote Speaker
Mark Caulfield, London, UK
Invited Speakers
Erika Cecchin, Aviano, Italy
Dyfrig Hughes, Bangor, Gwynedd, North Wales
Sir. Munir Pirmohamed, Liverpool, UK
Anneke Seller, Oxford, UK
Jesse Swen, Leiden, the Netherlands
Richard Turner, Liverpool, UK
Sarah Wordsworth, Oxford, UK
Scientific Program
08:45 – 09:20 Registration
09:20 – 09:30 Introduction – Welcome address
Sir. Munir Pirmohamed, Professor, University of Liverpool, Wolfson Centre for Personalised Medicine, Liverpool, UK
Session 1: Genomics Programmes
09:30 – 10:15 Keynote lecture: An overview of the 100,000 Genomes Project
Mark Caulfield, Professor and Director, William Harvey Research Institute, London, UK
10:15 – 10:45 Ubiquitous Pharmacogenomics
Jesse Swen, Associate Professor, Leiden University Medical Centre, Leiden, the Netherlands
10:45 – 11:15 Coffee break
Session 2: Education and Economics of Pharmacogenomics
11:15 – 11:45 Mind the gap: A strategy for upskilling the workforce on pharmacogenomics
Anneke Seller, Director; Genomics Educational Program, Oxford Radcliffe Hospitals NHS Trust, Oxford, UK, Oxford, UK
11:45 – 12:15 Economic evaluation in genomic medicine
Sarah Wordsworth, Associate Professor, University of Oxford, Nuffield Department of Population Health, Oxford, UK
12:15 – 12:45 Economics of pharmacogenetics
Dyfrig Hughes, Professor, University of Bangor, Centre for Health Economics and Medicines evaluation, Bangor, Gwynedd, North Wales
12:45 – 13:45 Lunch break
Session 3: Specialty Pharmacogenomics
13:45 – 14:15 Pharmacogenomics in oncology: From discovery to clinical implementation
Erika Cecchin, Senior Researcher, Centre for Oncology Research, Aviano, Italy
14:15 – 14:45 Cardiovascular Precision Medicine
Richard Turner, Postdoctoral Clinical Research Fellow, University of Liverpool, Liverpool, UK
14:45 – 15:00 Closing remarks
Sir. Munir Pirmohamed, Professor, University of Liverpool, Wolfson Centre for Personalised Medicine, Liverpool, UK
Registration
Online registration for this event is closed.
